Class IITerminatedD-0582-2016
Drug recall · January 27, 2016
Bevacizumab 1.25 mg/0.05 mL filled to 0.06 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal recall
Why: Presence of particulate matter: Presence of silicone oil microdroplets in bevacizumab syringes for intravitreal use.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Bevacizumab 1.25 mg/0.05 mL filled to 0.06 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal, Rx -- Pine Pharmaceuticals, 100 Colvin Woods Pkwy Suite 300, Tonawanda, NY 14150.
- Lots / codes
Lot #: 1648@7, exp. 12/20/2015; 1428@4, exp. 11/17/2015
- Quantity
- N/A
- Company
- Pine Pharmaceuticals, LLC, Tonawanda, NY
- Distribution
- Nationwide and Puerto Rico
- Initiated
- November 4, 2015 · Voluntary: Firm initiated
- Classified
- January 20, 2016
- Reported
- January 27, 2016
- Ended
- March 22, 2017
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Class IITerminatedJan 27, 2016Bevacizumab 1.25 mg/0.05 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal Rx -- Pine PharmaceuticalsPine Pharmaceuticals, LLC · D-0581-2016Class IITerminatedJan 27, 2016Bevacizumab 2 mg/0.08 mL in 3/10 mL 31 G 5/16" Syringe for intravitrealPine Pharmaceuticals, LLC · D-0583-2016Class IITerminatedJan 27, 2016Bevacizumab 2.5 mg/0.1 mL in 3/10 mL 31 G 5/16" Syringe for intravitreal injectionPine Pharmaceuticals, LLC · D-0584-2016
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.